• Apimeds Pharmaceuticals US appointed Christopher Kim as chief scientific officer, effective Aug. 5, 2026.
• Kim will lead scientific, clinical, regulatory development for the APITOX program, targeting approvals and commercialization.
• He has been closely associated with APITOX for many years, with scientific, technical, regulatory expertise tied to the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-086244), on August 06, 2026, and is solely responsible for the information contained therein.